Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly half of patients in a case series.

Am J Hematol. 2017;92(10):1085-1102. doi:org/10.1002/ajh.24876 National Library of Medicine. Mycosis fungoides. National Library of Medicine. Sézary syndrome. Lymphoma Research Foundation. Cutaneous B ...

The results from the Phase 2 in CTCL in Sezary syndrome and mycosis fungoides were presented at ASH 2023 and ASCO 2024 and have been highly encouraging, showing that lacutamab has the potential to ...

The drugs covered under the agreement include: — Poteligeo, for the treatment of mycosis fungoides or Sézary syndrome; — Oxlumo, for the treatment of hyperoxaluria type 1; — Epkinly ...

HALIFAX - Nova Scotia still hasn’t signed on to the federal government’s pharmacare plan, and the province’s Opposition New Democrats are wondering why. NDP Leader Claudia Chender said ...

The drugs covered under the agreement include: — Poteligeo, for the treatment of mycosis fungoides or Sézary syndrome; — Oxlumo, for the treatment of hyperoxaluria type 1; — Epkinly, for relapsed or ...

Today, the Honourable Kamal Khera, Canada’s Minister of Health, and the Honourable Michelle Thompson, Nova Scotia’s Minister of Health and Wellness, announced a bilateral agreement investing over $39 ...

In Canada, one in 12 people live with a rare disease, and for most people affected, the cost of treatment is unaffordable. Canadians deserve a health care system that provides timely access to quality ...

The common list of new drugs ensures that the National Strategy for Drugs for Rare Diseases delivers the most possible benefits to all patients with rare diseases. We will publish the names of drugs ...